IL-6 Levels Influence 3-Month All-Cause Mortality in Frail Hospitalized Older Patients

The multidimensional prognostic index (MPI) is a sensitive and specific prognosis estimation tool that accurately predicts all-cause mortality in frail older patients. It has been validated to assess the risk of 1month to 2-year mortality in frail older patients during hospitalization and after hospital discharge. However, whether the MPI is a valid prognostic tool for follow-up periods of different lengths remains to be validated. To this end, w e followed up 80 hospitalized patients (female=37, male 43) at least 75 years of age (mean age=82.6 +/- 4.4, range=75-94 years) to assess the 3-month all-cause mortality (mean follow -up=61.0 +/- 31.7 months [range 4-90 days]). Accordingly, patients were subdivided into low (MPI-1, score 0-0.33), moderate (MPI-2, score 0.34-0.66) and high (MPI-3, score 0.67-1) mortality risk classes. Moreover, baseline biochemical, inflammatory and metabolic parameters, as well as anamnestic and clinical characteristics, were obtained. Although the MPI-3 score was significantly associated with 3-month all-cause mortality in univariate analysis (HR=5.79, 95%0=1.77-18.92, p=0.004), a multivariate model indicated that only low albumin (HR41.33, 95 degrees/0CI41.160.68, p1.003) and high IL6 (HR=1.01, 95%CI=1.00-1.02, p=0.010) levels were significantly associated with 3month all-cause mortality. In conclusion, we suggest that measurement of IL6 as well as albumin, rather than the MPI score, may help in providing tailored therapeutic interventions to decrease short term mortality in older hospitalized individuals.

Automated summary

The multidimensional prognostic index (MPI) is a useful tool for predicting mortality in frail older patients, but in a study of 80 hospitalized patients aged 75 and above, only low albumin and high IL6 levels were significantly associated with 3-month all-cause mortality, rather than the MPI score.